Moderna & Merck announce 3-year data for mRNA-4157 in combination with Keytruda

The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer

AstraZeneca completes acquisition of Fusion Pharmaceuticals

This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs

Bristol Myers Squibb announces Opdivo Plus Yervoy (ipilimumab) improved overall survival for patients with unresectable hepatocellular carcinoma

Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population

Pfizer’s ADCETRIS regimen produces clinically meaningful improvement in overall survival in patients with DLBCL

Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen

Aurigene Pharmaceutical opens biologics facility in Genome Valley, Hyderabad

The state-of-the-art facility is equipped with best-in-class equipment and control systems

Merck's oncology pipeline of DDRi and ADC poised to advance cancer treatment

Merck shared updates on the company’s oncology pipeline and focused R&D approach

NTPC, Tata Memorial Centre launch cancer awareness initiative

The cancer screening and awareness camp will run for four months in the Mira Bhayander Region, benefiting approximately 5,000 police personnel

Takeda and Pfizer announce results from Positive Phase 3 HD21 trial of additional ADCETRIS combination in frontline hodgkin lymphoma

The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas

Supriya Lifescience FY24 PAT up 32%

The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23

Merck Specialities’ unique initiative to raise bladder cancer awareness